{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.0","upperLimit":"69.0","value":"60.7"},{"groupId":"OG001","lowerLimit":"49.4","upperLimit":"66.8","value":"58.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"Best Complete Response Rate (CRR), defined as the proportion of participants with a best response of at least CRu (including CR and CRu) after the first dose date of maintenance therapy and prior to any treatment change.","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"NUMBER","populationDescription":"All randomized participants in Arm A and Arm B, as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From the first dose date of maintenance therapy up to CR or CRu (up to approximately 432 weeks)","title":"Complete Response Rate (CRR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}